Last reviewed · How we verify
Consolidation Therapy
Consolidation Therapy is a Small molecule drug developed by Institute of Hematology & Blood Diseases Hospital, China. It is currently in Phase 3 development for Acute leukemia (post-induction consolidation), Lymphoma (post-induction consolidation). Also known as: Consolidation, intensification therapy, Post Remission Therapy, Postremission Therapy.
Consolidation therapy refers to a treatment strategy that follows initial induction therapy to eliminate residual disease and improve long-term outcomes in hematologic malignancies.
Consolidation Therapy is a treatment approach that has been studied in various clinical trials for conditions such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and High-risk Myelodysplastic Syndrome. The therapy involves interventions like ITMHA, Dexamethasone, and Mitoxantrone, and its mechanism is related to gene therapy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Consolidation Therapy |
|---|---|
| Also known as | Consolidation, intensification therapy, Post Remission Therapy, Postremission Therapy |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Consolidation therapy is a post-remission treatment approach commonly used in acute leukemias and lymphomas after achieving initial remission with induction chemotherapy. It aims to eradicate minimal residual disease and prevent relapse by administering additional cycles of chemotherapy or targeted agents. The specific mechanism depends on the underlying drugs used in the consolidation regimen.
Approved indications
- Acute leukemia (post-induction consolidation)
- Lymphoma (post-induction consolidation)
Common side effects
- Myelosuppression
- Infection
- Nausea and vomiting
- Mucositis
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Consolidation Therapy CI brief — competitive landscape report
- Consolidation Therapy updates RSS · CI watch RSS
- Institute of Hematology & Blood Diseases Hospital, China portfolio CI
Frequently asked questions about Consolidation Therapy
What is Consolidation Therapy?
How does Consolidation Therapy work?
What is Consolidation Therapy used for?
Who makes Consolidation Therapy?
Is Consolidation Therapy also known as anything else?
What development phase is Consolidation Therapy in?
What are the side effects of Consolidation Therapy?
Related
- Manufacturer: Institute of Hematology & Blood Diseases Hospital, China — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute leukemia (post-induction consolidation)
- Indication: Drugs for Lymphoma (post-induction consolidation)
- Also known as: Consolidation, intensification therapy, Post Remission Therapy, Postremission Therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing